Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up - Time to Buy?

Key Points

• Chugai Pharmaceutical's shares opened significantly higher at $24.60 after previously closing at $22.57, with the latest trading at $22.59.
• The company reported $0.20 earnings per share for the last quarter, with a revenue of $2.01 billion and a net margin of 33.08%.
• Chugai Pharmaceutical has a market cap of $74.34 billion and a price-to-earnings ratio of 28.60.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $22.57, but opened at $24.60. Chugai Pharmaceutical shares last traded at $22.59, with a volume of 1,568 shares trading hands.

Chugai Pharmaceutical Trading Up 0.9%

The firm has a 50 day moving average of $22.80 and a 200-day moving average of $24.49. The company has a market cap of $75.40 billion, a P/E ratio of 29.00 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last issued its earnings results on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. The company had revenue of $2.01 billion for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. Equities analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.